Literature DB >> 26526073

Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions.

C Arimany-Nardi1, H Koepsell2, M Pastor-Anglada1.   

Abstract

The SCL22A1 gene encodes the broad selectivity transporter hOCT1. hOCT1 is expressed in most epithelial barriers thereby contributing to drug pharmacokinetics. It is also expressed in different drug target cells, including immune system cells and others. Thus, this membrane protein might also contribute to drug pharmacodynamics. Up to 1000 hOCT1 polymorphisms have been identified so far, although only a small fraction of those have been mechanistically studied. A paradigm in the field of drug transporter pharmacogenetics is the impact of hOCT1 gene variability on metformin clinical parameters, affecting area under the concentration-time curve, Cmax and responsiveness. However, hOCT1 also mediates the translocation of a variety of drugs used as anticancer, antiviral, anti-inflammatory, antiemetic agents as well as drugs used in the treatment of neurological diseases among. This review focuses exclusively on those drugs for which some pharmacogenetic data are available, and aims at highlighting the need for further clinical research in this area.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26526073     DOI: 10.1038/tpj.2015.78

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  102 in total

1.  The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.

Authors:  M V Tzvetkov; S V Vormfelde; D Balen; I Meineke; T Schmidt; D Sehrt; I Sabolić; H Koepsell; J Brockmöller
Journal:  Clin Pharmacol Ther       Date:  2009-06-17       Impact factor: 6.875

Review 2.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

3.  The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1.

Authors:  Ali R Saadatmand; Sina Tadjerpisheh; Jürgen Brockmöller; Mladen V Tzvetkov
Journal:  Biochem Pharmacol       Date:  2012-02-10       Impact factor: 5.858

4.  Human organic cation transporter 1 is expressed in lymphoma cells and increases susceptibility to irinotecan and paclitaxel.

Authors:  Shivangi Gupta; Gerald Wulf; Maja Henjakovic; Hermann Koepsell; Gerhard Burckhardt; Yohannes Hagos
Journal:  J Pharmacol Exp Ther       Date:  2011-12-27       Impact factor: 4.030

5.  Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.

Authors:  Yuji Yamakawa; Akinobu Hamada; Reiko Nakashima; Misato Yuki; Chie Hirayama; Tatsuya Kawaguchi; Hideyuki Saito
Journal:  Ther Drug Monit       Date:  2011-04       Impact factor: 3.681

6.  Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.

Authors:  Sabrina Angelini; Simona Soverini; Gloria Ravegnini; Matt Barnett; Eleonora Turrini; Mark Thornquist; Fabrizio Pane; Timothy P Hughes; Deborah L White; Jerald Radich; Dong Wook Kim; Giuseppe Saglio; Daniela Cilloni; Ilaria Iacobucci; Giovanni Perini; Richard Woodman; Giorgio Cantelli-Forti; Michele Baccarani; Patrizia Hrelia; Giovanni Martinelli
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

7.  Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia.

Authors:  Takeru Nambu; Akinobu Hamada; Reiko Nakashima; Misato Yuki; Tatsuya Kawaguchi; Hiroaki Mitsuya; Hideyuki Saito
Journal:  Biol Pharm Bull       Date:  2011       Impact factor: 2.233

8.  Cloning and characterization of two human polyspecific organic cation transporters.

Authors:  V Gorboulev; J C Ulzheimer; A Akhoundova; I Ulzheimer-Teuber; U Karbach; S Quester; C Baumann; F Lang; A E Busch; H Koepsell
Journal:  DNA Cell Biol       Date:  1997-07       Impact factor: 3.311

9.  Effect of L364718, a new CCK antagonist, on amylase secretion in isolated rat pancreatic acini.

Authors:  R Hosotani; P Chowdhury; D McKay; P L Rayford
Journal:  Pancreas       Date:  1988       Impact factor: 3.327

10.  Genetic polymorphisms and haplotypes of the organic cation transporter 1 gene (SLC22A1) in the Xhosa population of South Africa.

Authors:  Clifford Jacobs; Brendon Pearce; Mornè Du Plessis; Nisreen Hoosain; Mongi Benjeddou
Journal:  Genet Mol Biol       Date:  2014-06       Impact factor: 1.771

View more
  16 in total

1.  Influence of pharmacogenetic polymorphisms and demographic variables on metformin pharmacokinetics in an admixed Brazilian cohort.

Authors:  Ana Beatriz Santoro; Mariana Rodrigues Botton; Claudio José Struchiner; Guilherme Suarez-Kurtz
Journal:  Br J Clin Pharmacol       Date:  2018-02-26       Impact factor: 4.335

Review 2.  Quantitative Proteomics in Translational Absorption, Distribution, Metabolism, and Excretion and Precision Medicine.

Authors:  Deepak Ahire; Laken Kruger; Sheena Sharma; Vijaya Saradhi Mettu; Abdul Basit; Bhagwat Prasad
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

3.  Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response.

Authors:  Mikael Kozyra; Magnus Ingelman-Sundberg; Volker M Lauschke
Journal:  Genet Med       Date:  2016-04-21       Impact factor: 8.822

4.  Exposure Characteristics of the Analogous β-Carboline Alkaloids Harmaline and Harmine Based on the Efflux Transporter of Multidrug Resistance Protein 2.

Authors:  Shuping Li; Yunpeng Zhang; Gang Deng; Yuwen Wang; Shenglan Qi; Xuemei Cheng; Yueming Ma; Yan Xie; Changhong Wang
Journal:  Front Pharmacol       Date:  2017-08-21       Impact factor: 5.810

Review 5.  Pharmacogenomic implications of the evolutionary history of infectious diseases in Africa.

Authors:  J L Baker; D Shriner; A R Bentley; C N Rotimi
Journal:  Pharmacogenomics J       Date:  2016-10-25       Impact factor: 3.550

6.  The global spectrum of protein-coding pharmacogenomic diversity.

Authors:  G E B Wright; B Carleton; M R Hayden; C J D Ross
Journal:  Pharmacogenomics J       Date:  2016-10-25       Impact factor: 3.550

7.  Organic cation transporter 1 (OCT1) modulates multiple cardiometabolic traits through effects on hepatic thiamine content.

Authors:  Xiaomin Liang; Sook Wah Yee; Huan-Chieh Chien; Eugene C Chen; Qi Luo; Ling Zou; Meiling Piao; Arias Mifune; Ligong Chen; Meredith E Calvert; Sarah King; Frode Norheim; Janna Abad; Ronald M Krauss; Kathleen M Giacomini
Journal:  PLoS Biol       Date:  2018-04-16       Impact factor: 8.029

Review 8.  Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes: A systematic review.

Authors:  Edith Pascale Mofo Mato; Magellan Guewo-Fokeng; M Faadiel Essop; Peter Mark Oroma Owira
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

Review 9.  Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition.

Authors:  Elisa Lozano; Oscar Briz; Rocio I R Macias; Maria A Serrano; Jose J G Marin; Elisa Herraez
Journal:  J Pers Med       Date:  2018-04-16

10.  Role of Human Organic Cation Transporter 1 (hOCT1) Polymorphisms in Lamivudine (3TC) Uptake and Drug-Drug Interactions.

Authors:  Cristina Arimany-Nardi; Gerard Minuesa; Thorsten Keller; Itziar Erkizia; Hermann Koepsell; Javier Martinez-Picado; Marçal Pastor-Anglada
Journal:  Front Pharmacol       Date:  2016-06-24       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.